DPP4 and type 2 diabetes mellitus: Although some systematic reviews and meta-analyses studies11,12 have found an advantage for DPP-IV inhibitors over existing therapies with oral antidiabetic compounds, they did not show a specific beneficial impact of DPP-IV inhibitors on reducing GV in T2DM patients.